Antiatherosclerotic effects of CSL112 mediated by enhanced cholesterol efflux capacity

The weeks right after a heart attack carry a stubbornly high risk of a second one. This review makes the case for CSL112, an infused form of the “good cholesterol” protein, as a way to blunt that early danger.

The mechanism is cholesterol efflux — the process by which HDL pulls cholesterol out of plaque. CSL112 is engineered to supercharge that capacity, and in preclinical and phase 2 work it raised efflux, dampened inflammation, and showed signs of stabilizing vulnerable plaque. The hope is a short course after a heart attack that defuses the most rupture-prone lesions during the highest-risk window.

The practical takeaway is conditional: CSL112 could become a post-heart-attack option — pending the phase 3 AEGIS-II outcomes trial. The resistance is well-earned skepticism, because earlier HDL-targeted drugs repeatedly failed despite elegant mechanisms.

We rate the evidence low: a strong mechanistic rationale and consistent early-phase data, but a review written largely by company-affiliated investigators, with the decisive outcome trial not yet read out. Its clinical significance is moderate and contingent — the unmet need is real, but the graveyard of failed HDL therapies means this one has to prove itself on hard endpoints before it counts.